Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
10 nov. 2022 01h01 HE
|
Celyad Oncology SA
Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1...
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
20 sept. 2022 01h00 HE
|
Celyad Oncology SA
GOSSELIES, Belgium and MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext...
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
05 août 2022 01h00 HE
|
Celyad Oncology SA
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food...
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
01 août 2022 01h01 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
28 juil. 2022 01h05 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Leadership Updates
24 juin 2022 01h05 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
31 mai 2022 02h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
17 mai 2022 16h05 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 18h12 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 16h05 HE
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...